The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  title={The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.},
  author={James W. Vardiman and Juergen Thiele and Daniel A. Arber and Richard Brunning and Michael J. Borowitz and Anna Porwit and Nancy Lee Harris and Michelle M Le Beau and Eva Hellstr{\"o}m-Lindberg and Ayalew Tefferi and Clara Derber Bloomfield},
  volume={114 5},
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the… 

Tables from this paper

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.

World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.

An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis and, in most cases, correlation of clinical, genetic, and morphologic findings is required for diagnosis and classification.

Health Organization ( WHO ) classification of tumors of the ematopoietic and lymphoid tissues : An overview with emphasis n the myeloid neoplasms ames

The aim of the revision was to incorporate new scientific and clinical information that has accumulated since the previous edition in order to refine diagnostic criteria for previously described neoplasms and to introduce newly recognized disease entities.

The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know.

  • D. Arber
  • Medicine, Biology
    Seminars in hematology
  • 2019
This review summarizes the WHO approach as well as the priority of specific features for disease classification of acute myeloid leukemia, including AML with myelodysplasia-related changes, and changes to specific categories.


rd edition) of the WHO classification of myeloid neoplasms included, for the first time in any widely used classification scheme, genetic information as diagnostic criteria not only for CML but also

Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification

The last four decades have witnessed major transformations in the approach to the diagnostic work-up and therapeutics in the field of hematology. The identification of the Philadelphia chromosome in

The 2016 revision to the World Health Organization classification of myelodysplastic syndromes

  • M. HongG. He
  • Medicine
    Journal of translational internal medicine
  • 2017
The new revised classification of MDS introduced refinements in the cytopenia and morphological changes, and also the influence of genetic information in MDS diagnosis and classification.



The World Health Organization (WHO) classification of the myeloid neoplasms.

The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.

Tumors of the bone marrow

The substantial focus on molecular genetic findings for each neoplasm parallels the ever-expanding role of genetics in disease classification and risk assessment and will provide readers with comprehensive information necessary for the clinical assessment of bone marrow neoplasms for years to come.

Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.

Clinical, morphologic, and cytogenetic criteria for this 2008 WHO AML category, AML with myelodysplasia-related changes, support the clinical, pathologic, cytogenetics, and molecular features of 100 patients evaluated.

Definition of acute biphenotypic leukemia.

BAL is an uncommon type of leukemia which probably arises from a multipotent progenitor cell and carries a poor prognosis, and it is likely that an intensive approach with high-dose therapy followed by bone marrow transplantation will be required to eradicate the disease permanently.

MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients.

The data support a reassessment of the WHO classification for AML in the light of a more biologic understanding of AML and confirm that MLD is often associated with an unfavorable cytogenetic profile.

Myelodysplastic syndromes: an historical perspective.

In 1900, Leube described a patient with severe megaloblastic anemia, preceding the development of overt leukemia, and not until recently have new validated risk factors been introduced, the most important being presence of a transfusion need.

A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases

This work proposes minimal diagnostic criteria and a simple classification scheme which, while based on accepted morphological features and conforming with the recent suggestions of the WHO, allows for the special problems of myelodysplastic diseases in children.

Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival.

Findings suggest that the detection of recurring cytogenetic abnormalities and multilineage dysplasia are the most significant features of current AML classification.

Long‐term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single‐center experience

Results indicate that outcomes for AML patients appear to be distinguished on the basis of the WHO classification, but the prognostic significance of multilineage dysplasia and prior therapy is lost after adjusting for cytogenetic risk and age.